Nanexa AB today announced that the company has signed an additional so-called Material Transfer and Feasibility Study Agreement with one of the company’s existing customers, for evaluation of the PharmaShell® technology with a specific biological drug substance.

Nanexa has previously collaborated with this big pharmaceutical company around the possibilities of combining the PharmaShell technology with different drug substances. This is further step in that collaboration.

“It is very exciting to continue our collaboration, which with this agreement enters into a new phase. We look forward to starting the work shortly and that this evaluation can generate results that can be the basis for a more extensive and long-term development agreement,” says David Westberg, CEO of Nanexa.

The agreement regulates, among other things, details of what shall be investigated, clarification regarding patent rights and a smaller determined fee to Nanexa for this evaluation.
 

For additional information, please contact:

David Westberg – CEO, Nanexa AB (publ) 
Phone: +46 70 942 83 03
Email: david.westberg@nanexa.se
www.nanexa.com
Erik Penser Bank is the company’s Certified Adviser and can be reached on +46 8 463 83 00, email: certifiedadviser@penser.se

About Nanexa AB (publ)

Nanexa AB is a nanotechnology drug delivery company focusing on the development of PharmaShell®, a new and groundbreaking drug delivery system with great potential for a number of medical substance types and indications. Within the framework of PharmaShell®, Nanexa devlops its own products and has collaboration agreements with several pharma companies, among others AstraZeneca.

Nanexa’s share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).

Attachments

Nanexa signs additional evaluation agreement

© Modular Finance, source Nordic Press Releases